YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
DelveInsight Business Research LLP The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab…
Johnson & Johnson JNJ stock has risen 18.3% in the past three months, backed by improving earnings and sales, a raised 2026 outlook, strong performance from newer medicines, pipeline wins and progress toward reducing the long-running uncer…
Looking for broad exposure to the Small Cap Growth segment of the US equity market? You should consider the Invesco S&P SmallCap Momentum ETF (XSMO), a passively managed exchange traded fund launched on March 3, 2005. The fund is sponsored…
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million…
On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The s…
U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additio…
NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investme…
Protagonist Therapeutics stock has delivered very strong returns over the past few years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like an obvious bargain. After such a strong move, in…
Protagonist Therapeutics recently reported that the U.S. FDA approved MIMRYLO (rusfertide), the first hepcidin mimetic peptide therapy for adults with polycythemia vera, a rare blood cancer. This regulatory milestone also activates milesto…
Why Protagonist Therapeutics Is Back In Focus After Investor Update Call Protagonist Therapeutics (PTGX) has drawn fresh attention after hosting a special call on 29 August 2026 to discuss its latest investor update, prompting many shareho…
Protagonist Therapeutics (NasdaqGM: PTGX) reported U.S. FDA approval of MIMRYLO (rusfertide) as a first in class hepcidin mimetic peptide for adults with polycythemia vera. The approval makes MIMRYLO the only FDA approved hepcidin mimetic…
On Friday, the U.S. Food and Drug Administration (FDA) approvedTakeda Pharmaceutical Co. Ltd.'s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. How MIMRYLO Combats Polycythemia Vera Polycythemia vera forces t…
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Joh…
The Vanguard Morningstar Growth ETF (NYSEMKT:VUG) provides ultra-low-cost exposure to domestic large-cap growth stocks, whereas the Invesco S&P SmallCap 600 Revenue ETF (NYSEMKT:RZG) targets small-cap growth companies by weighting them acc…
MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully Reduce Phlebotomy Burden…
Johnson & Johnson's JNJ pipeline is becoming an increasingly important growth driver as the company looks to offset future pressure from mature products such as Stelara and eventually Darzalex. The company has a particularly strong set of…
NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employ…
Johnson & Johnson JNJ is a leading player in oncology, with the segment accounting for around 29% of total company revenues and approximately 45% of Innovative Medicine sales. Beyond oncology, J&J has a strong presence in immunology and is…
The iShares Russell 2000 Growth ETF (NYSEMKT:IWO) provides broad, low-cost exposure to small-cap growth stocks, while the Invesco S&P SmallCap 600 Revenue ETF (NYSEMKT:RZG) uses a concentrated, revenue-weighted methodology. Investors seeki…
Key Points The iShares Russell 2000 Growth ETF manages $15 billion in assets, providing significantly higher liquidity than the $138 million Invesco S&P SmallCap 600 Revenue ETF. Invesco S&P SmallCap 600 Revenue ETF has outperformed over t…
Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activ PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The National Psoriasis Foundation recognizes August as Psoriasis Awareness Month, an annual initiative aimed at raising awareness, educating the public and supporting efforts to improve the lives of people affected by psoriasis and psoriat…
Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying abov…
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [ht…
The Vanguard Morningstar Mega Cap Growth ETF (NYSEMKT:MGK) offers a low-cost, technology-heavy approach to the largest U.S. companies, while the Invesco S&P SmallCap 600 Revenue ETF (NYSEMKT:RZG) provides targeted exposure to small-cap gro…
Protagonist Therapeutics (PTGX) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still…
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to a loss of $0.55 per share a year ago. These figures are adjusted for non-recurri…
ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026 Comprehensive Phase 2b Program with PN-881, an Oral IL-17 Antagonist for Psori…
NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employmen…
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.84 per share, missing the Zacks Consensus Estimate of $2.05 per share. This compares to earnings of $0.32 per share a year ago. These figures are adjusted for non-recurr…
Johnson & Johnson JNJ announced robust second-quarter 2026 results on July 15, beating estimates for both earnings and sales. While earnings rose 4.7%, sales rose 6.6% from the year-ago period. While the Innovative Medicine division's grow…
NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employme…
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 13: Sandisk Corporation SNDK: This company that designs and manufactures flash memory, storage solutions for consumers and enterp…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Fox Corporation FOX: This news, sports, and entertainment company has seen the Zacks Consensus Estimate for its next year earnings increasing 7.8% over the last 60 da…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. After a very large three year return, Protagonist Therapeutics now…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Protagonist Therapeutics (PTGX) has been in focus after two key mil…